Buchang Pharma declares dividend, unveils "Quality and Efficiency Enhancement" plan

Shandong Buchang Pharmaceuticals announced a 2025 semi-annual cash dividend of RMB 3.90 per 10 shares, totaling RMB 411,281,692.38, representing 65.52% of its semi-annual net profit. This distribution aligns with the company’s "Quality and Efficiency Enhancement for Shareholder Returns" action plan, which emphasizes continuous cash dividends and share repurchases. The company has conducted three share repurchases year-to-date, totaling 87,012,200 shares, at a cost of RMB 174,443,110.00.

The action plan outlines strategies for high-quality development, including focusing on core businesses in traditional Chinese medicine, chemical drugs, biological drugs, and vaccines. The company aims to enhance research and development, improve talent incentives, strengthen industry-university-research collaboration, and drive intelligent manufacturing. Additionally, it plans to optimize governance by enhancing internal controls and improving investor relations through transparent communication and diverse engagement channels.

As of June 30, 2025, the company's semi-annual net profit attributable to shareholders was RMB 627,701,257.33, with total operating revenue of RMB 5,663,836,253.89. The company's total assets stood at RMB 19,976,882,311.05.